Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 17/20 | 0.66 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | CCND2 | P30279 | 1/20 | 0.47 |
| ▸ | CCND3 | P30281 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14576373 | 0.90 | PTK2 (0.59) | PTK2 | |
| SCHEMBL17021742 | 0.86 | PTK2 (0.57) | PTK2FLT4CCND3 | |
| SCHEMBL14643605 | 0.84 | EGFR (0.56) | PTK2BRD4CDK4CCND1CCND2 | |
| SCHEMBL14576356 | 0.84 | PTK2 (0.66) | PTK2FLT4BRD4CDK4CCND1 | |
| SCHEMBL16656745 | 0.82 | BRD4 (0.47) | PTK2BRD4CDK4CCND1CCND2 | |
| SCHEMBL12479296 | 0.79 | PTK2 (1.00) | PTK2FLT4 | |
| SCHEMBL14576132 | 0.78 | PTK2 (1.00) | PTK2FLT4 | |
| SCHEMBL27933739 | 0.78 | PTK2 (0.77) | PTK2FLT4 | |
| SCHEMBL14643088 | 0.75 | PTK2 (0.84) | PTK2FLT4BRD4 | |
| SCHEMBL12479002 | 0.72 | PTK2 (1.00) | PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675793-B1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2018-08-08 | — | — | EP | disclosed |
| US-9421205-B2 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd. (AU) | 2016-08-23 | — | — | US | disclosed |
| US-9421205-B2 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd. (AU) | 2016-08-23 | — | — | US | disclosed |
| US-20150231135-A1 | FAK INHIBITORS | Cancer Therapeutics CRC Pty Ltd. (AU) | 2015-08-20 | — | — | US | disclosed |
| US-20150231135-A1 | FAK INHIBITORS | Cancer Therapeutics CRC Pty Ltd. (AU) | 2015-08-20 | — | — | US | disclosed |
| US-9012461-B2 | FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-04-21 | — | — | US | disclosed |
| CN-103534241-A | Fak inhibitor | CANCER THERAPEUTICS CRC PTY LTD | 2014-01-22 | — | — | CN | disclosed |
| US-20130324532-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-12-05 | — | — | US | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017194-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | PTK2 1/4885FLT4 617/4885BRD4 1155/4885 |
| US-20130324532-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | PTK2 1/4885FLT4 617/4885BRD4 1155/4885 |
| US-20150231135-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | PTK2 1/4885FLT4 791/4885BRD4 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.